Loading...
•
Sep 30, 2023
Blueprint Medicines Q3 2023 Earnings Report
Blueprint Medicines reported strong growth in AYVAKIT revenue and total revenue in Q3 2023.
Key Takeaways
Blueprint Medicines reported a strong third quarter, highlighted by a 90% year-over-year growth in AYVAKIT/AYVAKYT net product revenues, reaching $54.2 million, and a total revenue of $56.6 million. The company also saw a significant increase in the number of patients treated with AYVAKIT in the U.S., driven by ISM.
Achieved $54.2 million in AYVAKIT/AYVAKYT net product revenues, representing 90% growth year-over-year.
Total revenues reached $56.6 million in the third quarter of 2023.
Approximately 800 patients on AYVAKIT in the U.S. at the end of the third quarter, a 35% growth quarter-over-quarter.
Plan to present data from Part 1 of the HARBOR trial of elenestinib in ISM at ASH 2023.
Blueprint Medicines
Blueprint Medicines
Forward Guidance
The company anticipates continued steady growth in AYVAKIT revenue driven by both existing and new prescribers as they execute a disciplined approach to managing operating expenses and allocating capital to their most important investments.